SCHEMBL2897286

SCHEMBL2897286

OCC1CNCCC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864580 1.00 — —
SCHEMBL15720371 1.00 — —
Hydrochloric Acid SCHEMBL2901928 0.98 GBA1 (0.50) —
SCHEMBL29716692 0.81 — —
SCHEMBL505753 0.81 — —
SCHEMBL462864 0.81 — —
SCHEMBL505465 0.81 — —
SCHEMBL1313595 0.81 — —
SCHEMBL462863 0.81 — —
SCHEMBL505752 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558245-A2 USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES NOVO NORDISK A/S (DK) 2005-08-03 — — EP claimed
WO-2004037233-A2 USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES NOVO NORDISK A/S (DK) 2004-05-06 — — WO claimed
US-20040082641-A1 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases NOVO NORDISK A/S (DK) 2004-04-29 — — US claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2025-07-17 — — US disclosed
CN-119874700-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-04-25 — — CN disclosed
EP-4532487-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME Sanofi US Services Inc. (US) 2025-04-09 — — EP disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 — — US disclosed
CN-119301115-A Compounds for enhancing read-through of genes containing premature stop codons and methods of making and using the same 赛诺菲美国服务公司 2025-01-10 — — CN disclosed
CN-114945366-B HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-01-07 — — CN disclosed
US-11999753-B2 Tetrahydropyridopyrimidine pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2024-06-04 — — US disclosed
EP-1558245-A2 USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES NOVO NORDISK A/S (DK) 2005-08-03 — — EP disclosed
US-20050096278-A1 Antibacterial agents ELLSWORTH EDMUND L (US) 2005-05-05 — — US disclosed
WO-2005026145-A2 QUINOLONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-03-24 — — WO disclosed
US-20050054618-A1 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases RYTVED KLAUS ASGER (DK) 2005-03-10 — — US disclosed
WO-2004037233-A2 USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES NOVO NORDISK A/S (DK) 2004-05-06 — — WO disclosed
US-20040082641-A1 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases NOVO NORDISK A/S (DK) 2004-04-29 — — US disclosed
US-5863903-A ANTIDIABETIC AGENT NOVO NORDISK A/S (DK) 1999-01-26 — — US disclosed
EP-0749423-A1 PIPERIDINES AND PYRROLIDINES NOVO NORDISK A/S (DK) 1996-12-27 — — EP disclosed
WO-1995024391-A1 PIPERIDINES AND PYRROLIDINES NOVO NORDISK A/S (DK) 1995-09-14 — — WO disclosed
Send feedback